Sample	Gene	alle frequ	iant ele Jency F %)	c.DNA	Protein	Classification	Observations
		BM	PB				
Patient 1	FLT3	>5	>5	c.1773_1793dup	p.(Tyr597_Glu598ins AspValAspPheArgGluTyr)	TIER I	Prognostic and therapeutic indication in AML
	IDH2	>5	>5	c.419G>A	p.(Arg140Gln)	TIER I	Prognostic and therapeutic indication in AML
	NPM1	>5	>5	c.860_863dup	p.(Trp288Cysfs*12)	TIER I	Prognostic and therapeutic indication in AML
	ETV6	>5	>5	c.602T>C	p.(Leu201Pro)	TIER III	Not associated with AML
	SRSF2	>5	>5	c.284C>G	p.(Pro95Arg)	TIER I	Associated with AML
	SETBP1	>5	>5	c.691G>C	p.(Val231Leu)	TIER IV	Without clinical significance
	TET2	>5	>5	c.5162T>G	p.(Leu1721Trp)	TIER IV	Without clinical significance
	ASXL1	>5	>5	c.2444T>C	p.(Leu815Pro)	TIER IV	Without clinical significance
	ΚΙΤ	>5	>5	c.1621A>C	p.(Met541Leu)	TIER III	Associated with AML
	TP53	>5	>5	c.215C>G	p.(Pro72Arg)	TIER IV	Without clinical significance
Patient 2	TP53	>5	>5	c.375+5G>	unknown	TIER III	Not associated with AML
	TP53	>5	>5	c.215C>G	p.(Pro72Arg)	TIER IV	Without clinical significance
	CSF3R	>5	>5	c.1319G>A	p.(Arg440Gln)	TIER IV	Without clinical significance
	SETBP1	>5	>5	c.3388C>A	p.(Pro1130Thr)	TIER III	Not associated with AML
	TET2	>5	>5	c.1064G>A	p.(Gly355Asp)	TIER IV	Without clinical significance
	TET2	>5	>5	c.5284A>G	p.(lle1762Val)	TIER IV	Without clinical significance
	ASXL1	>5	>5	c.5284A>G	p.(Leu815Pro)	TIER IV	Without clinical significance